AI Consensus Investment Thesis
RxSight (RXST) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
STRONG BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
STRONG BUY$7.06
+35.8%5-Year
STRONG BUY$17
+222.8%Latest flagship insight
Cataract Technology Pioneer Trades Below Cash While Razor Blade Consumables Stabilize Enterprise
Research reports show high consensus that valuation is heavily discounted against cash reserves and recurring lens consumable revenues. While collapsing capital equipment placements and clinical chair-time burdens create ongoing headwinds, strategic collaboration milestones and expanding high-margin procedure volumes provide substantial long-term operating support.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Ray Dalio (Strategist), Machiavelli (Insider), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Universal Investor (Polymath), J.P. Morgan (Titan), Michael Burry (Vulture), Superintelligence (Anthropologist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in RxSight at the forecast anchor (2026-09-18): $32,281 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 5.58 | +7.23% | +7.23% | Lapse of the initial partnership refundability window secures liquid cash reserves above two hundred million dollars. Modest tax-loss selling exhausts as quantitative value screens recognize negative enterprise value, initiating early short-covering off depressed valuation lows. |
| Q1 2027 | 6.10 | +9.36% | +17.27% | Newly appointed executive leadership introduces formal annual commercial guidance, clarifying salesforce restructuring priorities. Stabilizing recurring consumable lens orders and corporate expense discipline reassure institutional investors, narrowing the steep market discount to tangible book value. |
| Q2 2027 | 6.61 | +8.38% | +27.09% | First-quarter results demonstrate sequential stabilization in consumable lens implant volumes across established surgical accounts. Steady gross margins above seventy-five percent mitigate high borrowing cost headwinds, validating that the razor-and-blade model is decoupling from hardware sales. |
| Q3 2027 | 7.06 | +6.87% | +35.83% | Targeted clinical support teams improve per-device lens utilization despite summer procedure seasonality. Progress on partner co-development milestones reassures markets regarding pipeline durability, supporting gradual valuation multiple expansion as quarterly operating cash burn steadily contracts. |
| Q4 2027 | 7.60 | +7.62% | +46.17% | Fourth-quarter elective surgical volume expands as patients utilize healthcare deductibles. Advancement in preclinical hybrid lens formulations directly addresses surgeon chair-time concerns, while contained administrative overhead reinforces investor confidence in multi-year balance sheet runway. |
| Q1 2028 | 8.27 | +8.74% | +58.95% | Full-year reporting confirms annual operating cash burn narrowed significantly as high-margin consumable sales outpaced hardware revenue. Preserved liquidity exceeding one hundred eighty million dollars dispels lingering solvency fears, prompting initial rating upgrades from sell-side analysts. |
| Q2 2028 | 9.05 | +9.50% | +74.05% | Achievement of technical feasibility criteria unlocks the first substantial partner development milestone, injecting non-dilutive capital. Tangible partnership execution reinforces the strategic value of proprietary adjustable optics, accelerating institutional accumulation across fundamental healthcare portfolios. |
| Q3 2028 | 9.46 | +4.47% | +81.83% | Competitive lens trialing by multinational incumbents temporarily moderates domestic procedure acceleration. However, disciplined operational spending and expanding international shipments to private Australian and European clinics defend consolidated gross margins near seventy-six percent. |
| Q4 2028 | 10.04 | +6.18% | +93.07% | Consumable lens procedures cross eighty percent of total corporate product revenue, cementing high-margin annuity characteristics. Year-end surgical demand combined with preliminary regulatory submissions for streamlined adjustment workflows strengthens multi-year earnings visibility. |
| Q1 2029 | 10.75 | +7.09% | +106.76% | Full-year results demonstrate the company approaching operating cash-flow neutrality, eliminating residual fears of dilutive equity financing. Operating leverage takes hold as recurring gross profits absorb baseline commercial infrastructure, supporting enterprise valuation re-rating. |
| Q2 2029 | 11.46 | +6.58% | +120.36% | Commercial roll-out of streamlined adjustment software reduces surgeon chair time across high-volume ambulatory centers. Enhanced practice throughput accelerates consumable lens reorders, while international distribution partnerships begin contributing high-margin incremental revenue. |
| Q3 2029 | 11.94 | +4.20% | +129.62% | Moderating benchmark interest rates alleviate borrowing pressures for ophthalmic practices, spurring selective light delivery console placements. Rebounding hardware sales augment expanding recurring consumable volume, driving double-digit revenue growth and expanding gross profit margins. |
| Q4 2029 | 12.59 | +5.46% | +142.15% | Partner regulatory filings for co-developed presbyopia-correcting lenses advance toward commercial clearance, validating global market potential. Maturing razor-and-blade economics deliver sustained positive free cash flow, transforming the company into a self-funding medtech operator. |
| Q1 2030 | 13.26 | +5.28% | +154.94% | Audited annual statements confirm the company's first full year of positive GAAP operating income. Demonstrating durable owner earnings validates management's turnaround strategy, attracting long-term growth-at-a-reasonable-price healthcare funds and expanding valuation multiples. |
| Q2 2030 | 13.98 | +5.49% | +168.94% | Regulatory approvals for the partner co-developed presbyopia lens trigger substantial milestone revenue. High-margin development income bolsters cash reserves, while commercial preparations begin across the partner's extensive global ophthalmology sales network. |
| Q3 2030 | 14.43 | +3.21% | +177.57% | High-volume cataract clinics increasingly standardize on post-operative adjustability to eliminate residual refractive error. Market share gains in the premium presbyopia segment reinforce pricing power, maintaining corporate gross margins comfortably above seventy-seven percent. |
| Q4 2030 | 15.06 | +4.32% | +189.56% | Initial global commercial shipments of co-developed lenses activate high-margin thirty percent royalty streams. Robust seasonal surgical volumes and royalty inflows accelerate EBITDA margin expansion, prompting board discussions regarding potential share repurchase authorizations. |
| Q1 2031 | 15.64 | +3.85% | +200.71% | Full-year financial reporting highlights double-digit return on invested capital driven by capital-light consumable growth and royalty revenue. Transparent cash generation and expanding royalty predictability command an expanded valuation multiple from broader equity markets. |
| Q2 2031 | 16.23 | +3.80% | +212.13% | International royalty revenue scales across European and Asian markets through the partner's dominant commercial channels. Strong operating cash flows fully fund ongoing optical research while preserving a pristine debt-free balance sheet with abundant liquidity. |
| Q3 2031 | 16.79 | +3.42% | +222.81% | The company concludes the five-year horizon as a profitable, established leader in customized ophthalmic optics. Sustained free cash flow compounding, royalty duration, and strategic acquisition appeal firmly anchor equity valuation at normalized medtech multiples. |
The core economic case rests on an asymmetry between distressed hardware multiples and an expanding high-margin consumable procedure annuity. Market pricing conflates capital equipment placement deceleration at ambulatory surgery centers with terminal technology obsolescence, discounting substantial liquid reserves and strategic partnership backing. As commercial salesforce realignment prioritizes account utilization over console pushes, high-margin lens consumables decouple operating performance from clinic capital budgets. The principal counterargument centers on persistent surgeon chair-time friction and incumbent portfolio bundling, which threaten to cap clinical adoption velocity before internal cash flow achieves self-funding operating breakeven.
Key insights
- Installed baseinstalled baseThe active set of deployed products or users already in operation with existing customers.View full glossary entry razor-and-blade economics generate seventy-five percent gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, ensuring each incremental procedure delivers powerful operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry that steadily compresses headline accounting deficits.
- Externalized international distribution and co-development commitments lower internal capital requirementscapital requirementsRegulatory mandates requiring banks to hold specific capital levels to ensure solvency and stability.View full glossary entry while securing prospective high-margin licensing royalties without dilutive corporate equity financing rounds.
- Workflow bottlenecks from multi-visit post-operative adjustments remain the critical operational risk, requiring pipeline biomaterial improvements to permanently unlock high-throughput ophthalmic surgical practices.
The business resembles a classic razor-and-blade model where a large cash balance protects the company while recurring lens sales grow. Investors panicked when clinic equipment sales slowed, pushing the stock down near its bank holdings. However, doctors who own the equipment continue buying premium lenses for surgery. The main threat is that busy eye surgeons dislike extra patient appointments, preferring simpler lenses from bigger competitors unless treatment visits decrease.
Key insights
- Recurring lens sales provide strong seventy-five percent profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry, steadily reducing quarterly losses as procedure numbers increase.
- A major industry partnership provides substantial non-dilutive development cash and opens global sales channels without costly expansions.
- Cutting required post-surgery patient appointments is essential to convince mainstream surgical practices to adopt these customizable lenses.
Deep Dive
The prevailing market narrative treats the company as a broken growth story whose capital equipment model stalled permanently amid restrictive interest rates and executive turnover. Wall Street consensus anchors heavily on 2025 revenue guidance cuts, withdrawn future outlooks, and ongoing securities litigation, assuming persistent operating losses will exhaust liquid assets before post-operative lens adjustability can surmount clinician workflow friction.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? The prevailing market narrative treats the company as a broken growth story whose capital equipment model stalled permanently amid restrictive interest rates and executive turnover. Wall Street consensus anchors heavily on 2025 revenue guidance cuts, withdrawn future outlooks, and ongoing securities litigation, assuming persistent operating losses will exhaust liquid assets before post-operative lens adjustability can surmount clinician workflow friction.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value through pronounced underpricing, pricing the equity near its net liquid assets while assigning negligible value to the operating business. The decisive analytical blind spot conflates cyclical hardware placement resistance with clinical obsolescence. In reality, over eleven hundred installed devices drive high-margin recurring lens consumables, while strategic alliance funding provides non-dilutive balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry support. The strongest counterargument remains that persistent clinician chair-time resistance and rival extended-depth lens bundling could permanently restrict procedure growth to a low-volume niche.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the reinstatement of formal annual guidance in early 2027 demonstrating sequential stabilization in consumable lens procedure volume and narrowed quarterly cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry. Verification that the strategic collaboration survives its initial refundability period, coupled with reportable co-development milestones and commercial salesforce reorientation around practice utilization, will dismantle terminal bankruptcy narratives and force institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry to re-rate the operating enterprise above cash value.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Capitulation
While sentiment aligns around deep fear and elevated volatility following sharp equity declines, reports diverge on cycle progression. Some view the asset as entering early operational stabilization, whereas others emphasize lingering capitulation risk until post-operative workflow bottlenecks are proven resolved.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive interest rates and sticky inflation presents a mixed backdrop. Elevated borrowing costs and tighter hospital budgets suppress ambulatory surgery center capital equipment financing and elective patient upgrade co-pays. However, an unencumbered balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry holding over two hundred million dollars in cash insulates the enterprise from debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry distress while generating non-operating interest income.
Advisor Disagreement
What do our AI Advisors disagree about most? The most consequential analytical debate centers on commercial turnaround mechanics and capital efficiencycapital efficiencyHow much value or profit is produced for each unit of invested capital.View full glossary entry. One perspective argues that new executive leadership and high-margin recurring lens consumables will organically achieve cash-flow neutrality by 2028, supported by non-dilutive partner milestones. Conversely, skeptical assessments assert that doubling salesforce headcount into an entrenched incumbent market will accelerate quarterly cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry beyond fifteen million dollars while partner agreements carry contractual refund and termination risks. Resolving this tension requires tracking whether lens implants per installed console stabilize across upcoming quarters without requiring operational expense growth.
Base-Case Forces
Event Risk ScoreVery High92/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Strategic alliance monetization and validation | Competitive Positioning | +65% | +60% | The strategic partnership injects sixty million dollars in upfront liquidity with up to one hundred forty million in contingent development milestones and thirty percent commercial royalties. This alliance validates proprietary adjustable optic technology, bypasses standalone international sales overhead, and provides non-dilutive capitalnon dilutive capitalFunding that does not require issuing new common equity and therefore does not directly reduce existing ownership percentages.View full glossary entry that accelerates the trajectory toward operating cash-flow breakeven. |
| Consumable razor-blade margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry | Operational Efficiency | +50% | +55% | Over eleven hundred installed light delivery consoles anchor a captive stream of recurring lens procedures carrying gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above seventy-five percent. As revenue mix shifts decisively toward consumable implants, cash generation decouples from volatile equipment cycles, allowing incremental procedure volume to deliver powerful operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry directly to company earnings. |
| Commercial realignment under veteran leadership | Management And Governance | +40% | +35% | Executive leadership restructuring pivots commercial strategy from pushing six-figure hardware consoles to optimizing lens utilization across existing clinic accounts. Realigning clinical support teams directly tackles customer onboarding and workflow friction, restoring predictability to domestic procedure volumes and reducing cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry while rebuilding institutional credibility with financial markets. |
| Demographic expansion in cataract surgery | Sector And Industry | +30% | +25% | Aging global demographics expand baseline cataract surgical volume, while patient demand for spectacle independence fuels premium intraocular lens conversion. Post-operative adjustability eliminates refractive surprise, granting surgeons superior visual precision over static toric lenses. This clinical differentiation supports premium self-pay pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and sustains dependable multi-year procedure demand. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Post-operative clinic chair-time bottleneck | Operational Efficiency | -35% | -35% | Requiring multiple post-operative UV light adjustment visits and weeks of protective eyewear compliance imposes heavy chair-time friction on busy ophthalmic practices. Surgeons frequently default to conventional premium lenses to maximize daily surgical throughput. Until streamlined single-visit protocols achieve commercial reality, workflow bottlenecks continue constraining practitioner adoption velocity. |
| Elevated interest rates freeze equipment | Macroeconomic And Macrofinancial | -30% | -30% | Elevated benchmark interest rates and stringent healthcare borrowing terms cause ambulatory surgery centers to delay six-figure capital equipment acquisitions. Light delivery console placements contracted sharply, extending sales cycles and depressing upfront hardware revenue. This capital rationing slows new practice onboarding and caps near-term expansion into unpenetrated surgical territories. |
| Aggressive incumbent portfolio bundling defense | Competitive Positioning | -25% | -25% | Multinational ophthalmology incumbents fiercely defend premium market share through aggressive pricing rebates and bundling intraocular lenses with phacoemulsification systems. Established competitors leverage extensive sales forces and clinical relationships to promote extended-depth lenses that require zero post-operative adjustments, capping pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and increasing standalone customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry. |
| Discretionary patient copayment affordability strain | Sector And Industry | -20% | -20% | Premium intraocular lenses require several thousand dollars in out-of-pocket patient copayments not covered by standard healthcare insurance. Sticky headline inflation and pressurized household disposable income prompt cost-conscious elderly patients to choose standard covered monofocal lenses. This consumer budget sensitivity dampens elective upgrade conversion rates across community ophthalmic clinics. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Collaboration agreement termination and refund | 25% | -50% | Technical hurdles or strategic divergence prompt the corporate partner to terminate the co-development agreement during review phases, forfeiting up to one hundred forty million dollars in milestones and demanding partial upfront capital refunds. The loss of strategic validation would shatter market confidence, draining cash reserves and triggering severe multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward distressed liquidation values. |
| Biomaterial phototoxicity regulatory safety recall | 15% | -65% | An unexpected emergence of late-onset retinal phototoxicity or lens material degradation triggers an FDA investigation, black-box safety warning, or product recall. Regulatory intervention would halt elective patient scheduling overnight, induce surgeon boycotts, and unleash substantial product liability claims that overwhelm balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry reserves and permanently impair enterprise earning power. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Strategic buyout by multinational partner | 30% | +120% | Following successful early co-development milestones, the multinational partner or another global ophthalmic major launches an outright acquisition of the company to secure proprietary adjustable optics and eliminate future royalty obligations. Given depressed enterprise valuation trading near cash reserves, a takeover offer would deliver an immediate control premium, realigning equity value with historical medical technology transaction multiples. |
| Single-session UV adjustment clearance | 25% | +85% | Securing regulatory clearance for next-generation light delivery algorithms and polymer chemistry collapses the multi-session adjustment protocol into a single post-operative treatment without protective glasses. Eliminating clinic chair-time friction removes the primary surgeon barrier, unleashing adoption across high-volume cataract practices and doubling annual consumable procedure volumes within twenty-four months. |
Company Financial Analysis
RxSight Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Headline financial results show a business navigating a major commercial pivot. Trailing revenue contracted to one hundred twenty-eight million dollars as clinic console purchases fell forty-eight percent in fiscal 2025. However, underlying consumable lens procedure volume grew twelve percent, providing a stable foundation beneath hardware volatility. Second-quarter 2026 revenue stabilized at thirty-three million seven hundred thousand dollars, aided by initial partnership licensing payments. This transition conceals improving underlying business quality behind headline accounting losses. Operating losses reached fifty-five million dollars over the trailing twelve months due to commercial expansion and legal costs. However, cash burn runs at roughly half that level because stock compensation is non-cash, and recurring lens sales are gradually replacing hardware as the primary revenue engine.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 134.5M | USD -38.9M | USD -19.3M |
| 2024 | USD 139.9M | USD -27.5M | USD -22.4M |
| 2023 | USD 89.1M | USD -48.6M | USD -46.4M |
| 2022 | USD 49M | USD -66.8M | USD -61.2M |
| 2021 | USD 22.6M | USD -48.7M | USD -46.6M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gross profit margins tell a remarkable story of structural improvement beneath headline operating deficits. Corporate gross margins surged from seventy point seven percent in 2024 to seventy-six point six percent in 2025, reaching seventy-six point seven percent in mid-2026. This expansion reflects an advantageous mix shift toward proprietary consumable lenses, which deliver significantly higher profitability than capital delivery consoles. Operating margins remain temporarily depressed at negative thirty-five point eight percent due to dedicated commercial sales infrastructure. However, product unit economics remain robust. As high-margin recurring lens procedures expand across the installed machine base and licensing income flows through with minimal added costs, operating leverage will steadily convert gross profits into sustainable operating earnings.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -48.2M | -35.8% | -29.0% |
| 2024 | USD -36.9M | -26.3% | -19.6% |
| 2023 | USD -50.1M | -56.2% | -54.6% |
| 2022 | USD -63.3M | -129.2% | -136.2% |
| 2021 | USD -52.8M | -233.6% | -215.5% |
Balance sheet and leverage
AI Review
The balance sheet stands as an unencumbered fortress that directly contradicts market distress. The company held two hundred eight million eight hundred thousand dollars in cash and short-term investments as of June 2026, with virtually zero funded bank debt. Total stockholders' equity stood at two hundred seventy-six million dollars, providing an overwhelming liquidity cushion relative to liabilities. Importantly, headline net cash exceeds the company's entire market capitalization, creating a rare net-net valuation floor. While fifty million dollars of partnership capital remains subject to conditional refund terms, trailing free cash burn of twenty-seven million dollars provides several years of operating runway. This liquidity eliminates near-term insolvency risk and shields shareholders from dilutive emergency financing.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 11M | USD 228.1M | USD 8.9M net cash | 10.95x |
| 2024 | USD 12.3M | USD 237.2M | USD 4.4M net cash | 11.36x |
| 2023 | USD 3M | USD 127.2M | USD 6.7M net cash | 8.06x |
| 2022 | USD 45M | USD 105.8M | USD 33.2M net debt | 7.81x |
| 2021 | USD 44.9M | USD 159.3M | USD 20.6M net debt | 15.92x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Physical capital requirements remain exceptionally low, with property and equipment expenditures consuming just under three percent of annual revenue. Manufacturing facilities in California are fully built out, allowing unit lens production to scale without expensive plant construction. Management directs cash into intangible engineering and optical algorithms rather than heavy machinery, keeping physical assets light and capital efficiency high. Crucially, ongoing research and development spending of thirty-eight million five hundred thousand dollars sustains platform enhancements to reduce patient clinic visits. By partnering with a global ophthalmic leader, the company externalizes expensive international distribution and clinical trial expenses onto its partner. This collaborative structure shields internal cash reserves while preserving substantial downstream commercial participation.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 3.8M | USD 38.5M |
| 2024 | USD 5.4M | USD 34.4M |
| 2023 | USD 4.8M | USD 29.1M |
| 2022 | USD 2.4M | USD 26M |
| 2021 | USD 1.9M | USD 24.5M |
Quarterly Forecast Scenarios
RxSight Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $4.888 | $5.6494 | $6.136 | $750.26 | |
| $4.9858 | $6.2159 | $6.995 | $736.44 | |
| $5.4843 | $6.7848 | $7.8344 | $743.40 | |
| $5.4388 | $7.3446 | $8.6179 | $755.15 | |
| $5.7651 | $8.0063 | $9.3935 | $776.22 | |
| $6.0534 | $8.7236 | $10.70 | $787.13 | |
| $6.4771 | $9.6233 | $12.42 | $802.83 | |
| $6.218 | $10.33 | $13.78 | $812.05 | |
| $6.5289 | $11.09 | $15.85 | $839.18 | |
| $6.7901 | $11.90 | $17.75 | $850.50 | |
| $6.9938 | $12.76 | $19.35 | $872.39 | |
| $6.784 | $13.60 | $22.06 | $885.51 | |
| $7.1232 | $14.51 | $24.26 | $909.56 | |
| $7.4081 | $15.36 | $27.17 | $916.13 | |
| $7.6304 | $16.36 | $29.35 | $936.51 | |
| $7.783 | $17.24 | $32.58 | $947.34 | |
| $8.0943 | $18.08 | $34.86 | $969.59 | |
| $8.3371 | $18.89 | $38.34 | $979.99 | |
| $8.5039 | $19.76 | $40.64 | $999.60 | |
| $8.759 | $20.64 | $44.30 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The analytical consensus identifies a common pattern: extreme valuation compression relative to liquid cash and resilient gross margins, paired with severe hardware placement deceleration. Heavily weighted analyses emphasize audited SEC filings, verifying that over two hundred million dollars in liquidity provides multi-year runway while recurring lens consumables decouple from capital equipment cycles. The strongest credible contrarian insight stresses that partnership capital is partially encumbered by refund liabilities and that aggressive commercial salesforce expansion could accelerate cash burn before chair-time bottlenecks resolve. Reports were downweighted where they lacked source receipts, assumed unverified near-term revenue tripling, or ignored contractual partnership termination contingencies. Relative allocations therefore prioritize assessments that distinguish recurring lens demand from one-off collaboration accounting while rigorously modeling clinic workflow frictions and equity dilution.
Universal Investor AI
The Polymath
GPT-6 AstraA top fourteen percent weight is warranted by exemplary evidence quality, verified SEC filings, and balanced causal modeling. The analysis uniquely accounts for refund liabilities encumbering upfront partner receipts, realistic share dilution from executive equity plans, and persistent competitive pressure from alternative implants.
Universal Investor AI
The Polymath
Opus 5A fourteen percent weight is justified by forensic financial analysis identifying that product gross margins fell to 71.2% excluding collaboration revenue. It provides superior contrarian insight into salesforce overhead expansion risks and scrutinizes contractual non-compete clauses governing partnership milestone payments.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAssigning a ten percent weight reflects rigorous Graham-style net-net valuation and clear causal analysis of consumable margin stabilization. The report accurately evaluates liquid reserves against enterprise value while prudently recognizing that capital equipment sales remain constrained by clinic financing hurdles.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashA ten percent weight rewards forensic disaggregation of hardware placement declines from resilient consumable lens procedure volumes. The report integrates verified trading and SEC documentation, providing an objective assessment of negative enterprise value and contained operating cash burn.
Michael Burry AI
The Vulture
Gemini 3.8 FlashA nine percent weight rewards acute contrarian analysis of negative enterprise value and net working capital protection. The report balances deep-value asymmetry against realistic risks of litigation cash drain and incumbent discounting, offering robust economic rationale for capital preservation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAn eight percent weight rewards granular analysis of clinical workflow bottlenecks and next-generation hybrid biomaterials. While lacking external source links, the report presents coherent causal modeling of chair-time compression and realistic assessments of partnership milestone timelines across the forecast horizon.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashA seven percent weight recognizes thorough institutional examination of partner commercialization rails and balance sheet health. However, the path assumes an aggressive multiple re-rating toward three times book value that slightly discounts near-term competitive trialing pressure from entrenched multinational cataract incumbents.
Elon Musk AI
The Visionary
Gemini 3.8 FlashA seven percent weight reflects strong physical and optical domain insights regarding post-operative polymer adjustments. However, the forecast models an aggressive procedural utilization inflection that understates ambulatory surgery center capital hesitation and ongoing securities litigation defense overhead.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashA six percent weight reflects sound analysis of commercial execution bottlenecks and installed base utilization. The rationale acknowledges executive leadership changes under Mottiwala while maintaining a measured path, though it lacks direct SEC filing verification to support a larger allocation.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashA six percent weight incorporates rigorous debt-cycle and macroeconomic regime analysis. The report effectively articulates how high interest rates freeze clinic capital budgets while net cash protects corporate solvency, though its scenario path relies on unverified revenue acceleration.
Universal Investor AI
The Polymath
Gemini 3.8 FlashA five percent weight reflects sound razor-and-blade commercial framing and balance sheet resilience. However, the report lacks external research citations and underweights potential clinical workflow delays in developing next-generation single-session light adjustment protocols.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashA four percent weight captures thoughtful qualitative evaluation of surgeon behavioral friction and chair-time resistance. Nevertheless, the absence of independent research receipts and an optimistic long-term multiple trajectory warrant a modest relative weighting in the synthesis.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashA zero weight is justified because the report provides no independent research sources or primary regulatory verification. Furthermore, its seven-hundred-percent five-year return trajectory assumes flawless multiple expansion while overlooking material partnership refund liabilities and persistent surgeon chair-time bottlenecks.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashA zero weight is assigned due to the complete absence of independent source receipts and vague commercial projections. The thesis assumes rapid multiple re-expansion without addressing contractual refund liabilities, ongoing executive restructuring, or recent quarterly product revenue contractions.
Research Provenance
References & Context
This RxSight consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 106 deduplicated sources retained for this batch.
- 01Premarket Approval (PMA)accessdata.fda.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 0310-Qsec.gov
- 048-Ksec.gov
- 058-Ksec.gov
- 06EX-10.3sec.gov
- 07RxSight, Inc. - Form 10-Q - FY2026sec.gov
- 08RxSight, Inc. - Form 8-K - FY2026sec.gov
- 09RxSight, Inc. - Form 8-K - FY2026sec.gov
- 10www.sec.govsec.gov
- 11RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook - BioSpacebiospace.com
- 12RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook By Investing.comca.investing.com
- 13RxSight (NASDAQ:RXST) Cut to Sell at Wall Street Zen - Daily Politicaldailypolitical.com
- 14RxSight, Inc. (RXST) Stock Analysis: Evaluating The 46% Potential Upside In Medical Device Innovationdirectorstalkinterviews.com
- 15RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...finance.yahoo.com
And 91 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2019-12-31–2025-12-31, 7 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.